Professor Jens Juul Holst Receives the Harrington Prize for Innovation in Medicine – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Health > News > 2017 > Harrington Prize

14 March 2017

Professor Jens Juul Holst Receives the Harrington Prize for Innovation in Medicine

Harrington Prize

On 21 April 2017 Professor Jens Juul Holst receives the prestigious international Harrington Prize for Innovation in Medicine. The prize is given to scientists who have delivered notable scientific results with great potential within innovation, creativity and clinical application.

His discovery of the GLP-1 hormone and translation of these results into new treatments for widespread metabolic diseases like diabetes is the reason why Professor Jens Juul Holst receives the 2017 Harrington Prize for Innovation in Medicine. The prize was established in 2014 by the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio and the American Society for Clinical Investigation (ASCI), and it honours scientists who have moved science forwards through innovative discoveries with potential for clinical application.

’I am very happy to receive this prize, especially as European/Nordic research rarely attracts attention in North America. So it is a bit of a breakthrough’, says Jens Juul Holst from the Section of Endochrinological Research at the Department of Biomedical Sciences/the Novo Nordisk Center for Basic Metabolic Research.

Jens Juul Holst’s research achievements are among the most extensive in the world within diabetes. He is one of the most cited researchers in Europe, and he has published more than 1,200 scientific articles. He is cited 3,500 times a year, and concurrently with his work he has received large international prizes for his research. The discovery of the GLP-1 hormone is not just a scientific breakthrough; it has also given chronically ill patients new hope and formed a basis for modern diabetes treatment.

Best of 58 Nominations
Jens Juul Holst shares the Harrington Prize with Dr Daniel J. Drucker from Mount Sinai Hospital in Canada and Dr Joel F. Habener from Massachusetts General Hospital in the United States, who have also delivered notable achievements within the treatment of metabolic diseases. A total of 58 candidates from 49 institutions have been nominated for the prize, and the committee consisting of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board has selected these three scientists.

‘The three notable scientists are an example of health science at its best – from fundamental discoveries to medical breakthroughs in the clinical world, affecting millions of people all over the world’, says President of the Harrington Discovery Institute Dr Jonathan Stamler, who holds the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the University Hospitals Cleveland Medical Center and the Case Western Reserve University School of Medicine.

In connection with the prize-giving on 21 April each of the three researchers will give a special lecture, ‘The Harrington Prize Lecture’, at the Association of American Physicians/ASCI/American Physician Scientists Association Joint Meeting and publish an essay in the Journal of Clinical Investigation. 

Contact: 
Professor Jens Juul Holst, email: jjholst@sund.ku.dk, phone: +45 35 32 75 18